GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.

Xiayun YangQin ZhangShuxuan LiRaman DevarajanBinjie LuoZenglai TanZixian WangNikolaos GiannareasTomasz WentaWenlong MaYuqing LiYuehong YangAki ManninenSong WuGong-Hong Wei

Published in: Journal of experimental & clinical cancer research : CR (2023)

Our study prioritizes causal genomic amplification genes with prognostic values in PCa and reveals the pivotal roles of GATA2 in transcriptionally activating the expression of its own and TGFβ1, thereby co-opting to TGFβ1/SMAD4 signaling and RFX6 at 6q22 to modulate PCa predisposition and progression.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
prostate cancer
transcription factor
copy number
signaling pathway
poor prognosis
genome wide
nucleic acid
bioinformatics analysis